Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease

Linda A. Feagins, Akbar Waljee, Jason K. Hou, Phillip Gu, Steven Kanjo, Vivek Rudrapatna, Daisha J. Cipher, Shail Govani, Jill Gaidos

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Biological therapies are effective for inducing and maintaining remission in inflammatory bowel disease (IBD), but patients often require changes in biological agents over the course of their illness. We sought to evaluate the rate of and reasons for discontinuing biological agents and to identify risk factors for their discontinuation. Methods: We performed a retrospective cohort study across 4 VA hospital systems (Dallas, TX; Houston, TX; Ann Arbor, MI; Richmond, VA). Patients with IBD who were started on biological therapy between 1998 and 2015 were identified, and their medical records were reviewed to confirm the diagnosis of IBD and to collect study data. Results: Of 1969 patients with IBD; 256 were treated with 346 courses of therapy. By 6 months after initiation of therapy, 82 (24%) had stopped the biological agent. Among patients starting their first biological agent, 21.5% had stopped by 6 months. Patients taking a concomitant thiopurine and those with ileocolonic disease or a nonpenetrating, nonstricturing phenotype were less likely to discontinue biological therapy, whereas those taking 5-ASA concomitantly were more likely to discontinue biological therapy. The most common reasons for discontinuation were primary nonresponse (40%) and adverse drug reactions (29%). Conclusions: In conclusion, in a large multicenter VA cohort, we found that 24% of patients who are prescribed a biological stop their treatment early, most commonly for primary nonresponse or for an adverse drug reaction. Consideration should be given to treating patients with a concomitant thiopurine if at all possible, as this reduces the likelihood of early discontinuation.

Original languageEnglish (US)
Pages (from-to)1434-1439
Number of pages6
JournalInflammatory Bowel Diseases
Volume23
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Biological Therapy
Veterans
Inflammatory Bowel Diseases
Biological Factors
Incidence
Drug-Related Side Effects and Adverse Reactions
Medical Records
Cohort Studies
Therapeutics
Retrospective Studies
Phenotype

Keywords

  • anti-TNF
  • Crohn's
  • discontinuation
  • inflammatory bowel disease
  • ulcerative colitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease. / Feagins, Linda A.; Waljee, Akbar; Hou, Jason K.; Gu, Phillip; Kanjo, Steven; Rudrapatna, Vivek; Cipher, Daisha J.; Govani, Shail; Gaidos, Jill.

In: Inflammatory Bowel Diseases, Vol. 23, No. 8, 01.08.2017, p. 1434-1439.

Research output: Contribution to journalArticle

Feagins, LA, Waljee, A, Hou, JK, Gu, P, Kanjo, S, Rudrapatna, V, Cipher, DJ, Govani, S & Gaidos, J 2017, 'Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease', Inflammatory Bowel Diseases, vol. 23, no. 8, pp. 1434-1439. https://doi.org/10.1097/MIB.0000000000001145
Feagins, Linda A. ; Waljee, Akbar ; Hou, Jason K. ; Gu, Phillip ; Kanjo, Steven ; Rudrapatna, Vivek ; Cipher, Daisha J. ; Govani, Shail ; Gaidos, Jill. / Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease. In: Inflammatory Bowel Diseases. 2017 ; Vol. 23, No. 8. pp. 1434-1439.
@article{092313dd7bd14e65a316809275494eac,
title = "Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease",
abstract = "Background: Biological therapies are effective for inducing and maintaining remission in inflammatory bowel disease (IBD), but patients often require changes in biological agents over the course of their illness. We sought to evaluate the rate of and reasons for discontinuing biological agents and to identify risk factors for their discontinuation. Methods: We performed a retrospective cohort study across 4 VA hospital systems (Dallas, TX; Houston, TX; Ann Arbor, MI; Richmond, VA). Patients with IBD who were started on biological therapy between 1998 and 2015 were identified, and their medical records were reviewed to confirm the diagnosis of IBD and to collect study data. Results: Of 1969 patients with IBD; 256 were treated with 346 courses of therapy. By 6 months after initiation of therapy, 82 (24{\%}) had stopped the biological agent. Among patients starting their first biological agent, 21.5{\%} had stopped by 6 months. Patients taking a concomitant thiopurine and those with ileocolonic disease or a nonpenetrating, nonstricturing phenotype were less likely to discontinue biological therapy, whereas those taking 5-ASA concomitantly were more likely to discontinue biological therapy. The most common reasons for discontinuation were primary nonresponse (40{\%}) and adverse drug reactions (29{\%}). Conclusions: In conclusion, in a large multicenter VA cohort, we found that 24{\%} of patients who are prescribed a biological stop their treatment early, most commonly for primary nonresponse or for an adverse drug reaction. Consideration should be given to treating patients with a concomitant thiopurine if at all possible, as this reduces the likelihood of early discontinuation.",
keywords = "anti-TNF, Crohn's, discontinuation, inflammatory bowel disease, ulcerative colitis",
author = "Feagins, {Linda A.} and Akbar Waljee and Hou, {Jason K.} and Phillip Gu and Steven Kanjo and Vivek Rudrapatna and Cipher, {Daisha J.} and Shail Govani and Jill Gaidos",
year = "2017",
month = "8",
day = "1",
doi = "10.1097/MIB.0000000000001145",
language = "English (US)",
volume = "23",
pages = "1434--1439",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease

AU - Feagins, Linda A.

AU - Waljee, Akbar

AU - Hou, Jason K.

AU - Gu, Phillip

AU - Kanjo, Steven

AU - Rudrapatna, Vivek

AU - Cipher, Daisha J.

AU - Govani, Shail

AU - Gaidos, Jill

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background: Biological therapies are effective for inducing and maintaining remission in inflammatory bowel disease (IBD), but patients often require changes in biological agents over the course of their illness. We sought to evaluate the rate of and reasons for discontinuing biological agents and to identify risk factors for their discontinuation. Methods: We performed a retrospective cohort study across 4 VA hospital systems (Dallas, TX; Houston, TX; Ann Arbor, MI; Richmond, VA). Patients with IBD who were started on biological therapy between 1998 and 2015 were identified, and their medical records were reviewed to confirm the diagnosis of IBD and to collect study data. Results: Of 1969 patients with IBD; 256 were treated with 346 courses of therapy. By 6 months after initiation of therapy, 82 (24%) had stopped the biological agent. Among patients starting their first biological agent, 21.5% had stopped by 6 months. Patients taking a concomitant thiopurine and those with ileocolonic disease or a nonpenetrating, nonstricturing phenotype were less likely to discontinue biological therapy, whereas those taking 5-ASA concomitantly were more likely to discontinue biological therapy. The most common reasons for discontinuation were primary nonresponse (40%) and adverse drug reactions (29%). Conclusions: In conclusion, in a large multicenter VA cohort, we found that 24% of patients who are prescribed a biological stop their treatment early, most commonly for primary nonresponse or for an adverse drug reaction. Consideration should be given to treating patients with a concomitant thiopurine if at all possible, as this reduces the likelihood of early discontinuation.

AB - Background: Biological therapies are effective for inducing and maintaining remission in inflammatory bowel disease (IBD), but patients often require changes in biological agents over the course of their illness. We sought to evaluate the rate of and reasons for discontinuing biological agents and to identify risk factors for their discontinuation. Methods: We performed a retrospective cohort study across 4 VA hospital systems (Dallas, TX; Houston, TX; Ann Arbor, MI; Richmond, VA). Patients with IBD who were started on biological therapy between 1998 and 2015 were identified, and their medical records were reviewed to confirm the diagnosis of IBD and to collect study data. Results: Of 1969 patients with IBD; 256 were treated with 346 courses of therapy. By 6 months after initiation of therapy, 82 (24%) had stopped the biological agent. Among patients starting their first biological agent, 21.5% had stopped by 6 months. Patients taking a concomitant thiopurine and those with ileocolonic disease or a nonpenetrating, nonstricturing phenotype were less likely to discontinue biological therapy, whereas those taking 5-ASA concomitantly were more likely to discontinue biological therapy. The most common reasons for discontinuation were primary nonresponse (40%) and adverse drug reactions (29%). Conclusions: In conclusion, in a large multicenter VA cohort, we found that 24% of patients who are prescribed a biological stop their treatment early, most commonly for primary nonresponse or for an adverse drug reaction. Consideration should be given to treating patients with a concomitant thiopurine if at all possible, as this reduces the likelihood of early discontinuation.

KW - anti-TNF

KW - Crohn's

KW - discontinuation

KW - inflammatory bowel disease

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85026479343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026479343&partnerID=8YFLogxK

U2 - 10.1097/MIB.0000000000001145

DO - 10.1097/MIB.0000000000001145

M3 - Article

C2 - 28570429

AN - SCOPUS:85026479343

VL - 23

SP - 1434

EP - 1439

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 8

ER -